Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 55 out of 100. Disparities

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

. Longitudinally, older age (OR=1.14 [1.06-1.22], p<.001), higher levels of p-tau217 (OR=10.37 [3.00-35.02], p<.001) and higher neuropsychiatric symptoms (OR=1.19 [1.02-1.39], p=.023) were associated with higher odds of progression to dementia. MCI is etiologically heterogeneous. The presence of Alzheimer's pathology defined by elevated plasma p-tau217 in individuals with MCI significantly worsens prognosis. Neuropsychiatric symptoms may contribute to cognitive complaints and risk for progressive decline irrespective of AD pathology. Plasma p-tau217 can inform our understanding of base rates of different MCI phenotypes on a larger scale. As with other AD biomarkers, frequency of elevated plasma p-tau217 and odds of progression to dementia requires careful consideration of recruitment source (clinic- vs. community-based), especially across ethno-racially diverse older adults. Ongoing integration of emerging neurodegenerative disease biomarkers with detailed clinical evaluations will continue to improve treatment specificity and prognosis.

What this study adds

Evidence grade: Moderate

This is a cross-sectional study of 104 participants. In people with mild cognitive impairment, elevated plasma p-tau217 was linked to much higher odds of progressing to dementia, indicating that this blood marker can help define who has Alzheimer's pathology and a worse prognosis. Reported effect size: 52.9%; 49.0%; 68.5%.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Asken, B. M., Curiel, R. E., Crocco, E., Armstrong, M. J., Levy, S.-A. T., Arias, F., et al. (2025). Informing etiological heterogeneity of mild cognitive impairment and risk for progression to dementia with plasma p-tau217. The Journal of Prevention of Alzheimer s Disease. https://doi.org/10.1016/j.tjpad.2024.100011

Vancouver

Asken BM, Curiel RE, Crocco E, Armstrong MJ, Levy S.-AT, Arias F, et al. Informing etiological heterogeneity of mild cognitive impairment and risk for progression to dementia with plasma p-tau217. The Journal of Prevention of Alzheimer s Disease. 2025. doi:10.1016/j.tjpad.2024.100011. PMID: 39800468.

BibTeX

@article{asken2025-39800468,
  author  = {Asken, Breton Michael and Curiel, Rosie E. and Crocco, Elizabeth and Armstrong, Melissa J. and Levy, Shellie-Anne T. and Arias, Franchesca and Rosselli, Mónica and Uribe, Idaly Vélez and others},
  title   = {{Informing etiological heterogeneity of mild cognitive impairment and risk for progression to dementia with plasma p-tau217}},
  journal = {The Journal of Prevention of Alzheimer s Disease},
  year    = {2025},
  doi     = {10.1016/j.tjpad.2024.100011},
  pmid    = {39800468},
  url     = {https://doi.org/10.1016/j.tjpad.2024.100011}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

In people with mild cognitive impairment, elevated plasma p-tau217 was linked to much higher odds of progressing to dementia, indicating that this blood marker can help define who has Alzheimer's pathology and a worse prognosis. The findings are about prognosis and classification, not about a treatment or cure.

Study details

How this study scored 55/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 0 of 4; Study design 4 of 12; Strength of evidence 3 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 2 of 4; Effect reported 2 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited 2 of 7; Citations per year 2 of 5; Impact for its field and year 3 of 6; Cited by studies here 1 of 6; Still being cited 1 of 4; Senior author's track record 4 of 4; Institution's track record 1 of 3; Multicenter collaboration 2 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. Total 55 of 100.55 of 100 points earned45 not earned

Published in a peer-reviewed journal, and it is a snapshot of people at one point in time. Scored zero for randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (The Journal of Prevention of Alzheimer s Disease)
Journal's citation record 0 / 4 The Journal of Prevention of Alzheimer s Disease: journal h-index 63 (OpenAlex, 2026-10-29)
Study design 4 / 12 A snapshot of people at one point in time
Strength of evidence 3 / 5 Rated “moderate” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2025 — within 3 year(s) of the newest study here
Sample size 2 / 4 104 participants
Effect reported 2 / 3 Effect reported as a number, without an interval or test
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 2 / 7 Cited 12 times (OpenAlex, 2026-10-10)
Citations per year 2 / 5 4.0 citations a year over 3 year(s) since 2025
Impact for its field and year 3 / 6 Cited 7.6× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 1 / 6 Cited by 1 other studies in this library
Still being cited 1 / 4 Cited 12 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 4 / 4 Last-listed author Glenn E. Smith: h-index 104 (OpenAlex, whole career)
Institution's track record 1 / 3 University of Florida: institution h-index 1,303 (OpenAlex)
Multicenter collaboration 2 / 3 OpenAlex lists 5 institution(s) in 1 country
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 39800468)
Free to read 2 / 2 Free to read
Total 55 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 22.

Later studies that cite this one

1 study in the alzhub library lists this one in its references.

Related studies in Disparities from nearby years

Also tagged “phosphorylated”

732 studies in the library carry the topic tag “phosphorylated”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 732 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Disparities

See all studies in Disparities →